A tour of recent patent applications addressing antibacterial resistance

Bibliography

• BARKER KF: Antibiotic resistance: a current perspective. Br. Clin. Pharmacol (1999) 48:109–124.
   PubMed Web of Science ®Google Scholar
• DeBONO M, ABBOTT BJ, MOLLOY RM et al.: Enzymatic and chemical modification of lipopeptide antibiotic A21978: the synthesis and evaluation of daptomycin (LY146032)../ Antibio. (1988) 41:1093–1105.
   Google Scholar
• CANEPARI P, FONTANA R, SATTA G:New targets for the mechanism of action of antibiotics active against Gram-positive cocci.' Chemother: (1991) 3\(Suppl. 1):141–14.3.
   Google Scholar
• ALLEN NE, HOBBS JN, ALBORN WEJr.: Inhibition of peptidoglycan biosynthesis in Gram-positive bacteria by LY146032. Antimicrob. Agents Chemother. (1987) 31:1093–1099.
   Google Scholar
• OLESON FB Jr., BERMAN CL, KIRKPATRICK JB, REGAN KS, LAI JJ, TALLY FP: Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob. Agents Chemother: (2000) 44:2948–2953.
   PubMedGoogle Scholar
• HILL J, FINN J, PARR I et al: Novel Lipopeptides 1: Synthesis and Biological Activity of Ornithine Amino Amide Analogs of Daptomycin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago (2001) Papers 1150.
   Google Scholar
• HILL J, FINN J, PARR I et al: Novel Lipopeptides 2: Synthesis and biological activity of aromatic amide analogs of daptomycin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA, (2001) papers 1151.
   Google Scholar
• HILL J, FINN J, LAZAROVA T et al.: Novel Lipopeptides 3: Synthesis and biological activity of kynurenine analogs of daptomycin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA (2001) paper 1152.
   Google Scholar
• CHEN DZ, PATEL DV, HACKBARTH CJet al.: Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry (2000) 39:1256–1262.
   Google Scholar
• THEN RL: History and future of antimicrobial diaminopyrimidines..I. Chemother. (1993) 5:361–368.
   PubMed Web of Science ®Google Scholar
• HECKER SJ, LILLEY SC, WERNER KM: Hygromycin A: preparation of aminocyclitol analogs defining the minimum functionality required for biological activity. BioMed. Chem. Lett. (1992) 23:1043.
   Google Scholar
• GUERRER MC, MODOLELL J: Hygromycin A, a novel inhibitor of ribosome peptidyltransferase. Ear. Biochem. (1980) 107:409–414.
   PubMedGoogle Scholar
• EGGER H, REINSHAGEN H: New pleuromutilin derivatives with enhanced antimicrobial activity: I. Synthesis J. Antibiot. (1976) 29:915–922.
   PubMed Web of Science ®Google Scholar
• EGGER H, REINSHAGEN H: New pleuromutilin derivatives with enhanced antimicrobial activity: II. Structure-activity correlations. J. Antibia (1976) 29:923–927.
   Google Scholar
• HOGENAUER G, RUF C: Ribosomal binding region for the antibiotic tiamulin: stoichiometry, subunit location, and affinity for various analogs. Antimicrob. Agents Chemother. (1981) 19:260–265.
   PubMed Web of Science ®Google Scholar
• POULSON SM, KARLSSON M, JOHANSSON LB, VESTER B: The pleuromutilin drugs tiamulin and valnemulin bind to the RNA at the peptidyl transferase centre on the ribosome. Ma Microbiol (2001) 41:1091–1099.
   PubMedGoogle Scholar
• HEILMANN C, JENSEN L, JENSEN JS et al.: Treatment of resistant Mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. Infection (2001) 43:234–238.
   Web of Science ®Google Scholar
• BERGLER H, WALLNER P, EBELING A et al.: Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of Escherichia coil. Biol. Chem. (1994) 269:5493–5496.
   Google Scholar
• HEATH RJ, ROCK CO: Regulation of fatty acid elongation and initiation by acyl-acyl carrier protein in Escherichia coil. .1. Biol. Chem. (1996) 271:1833–1836.
   PubMed Web of Science ®Google Scholar
• BERGLER H, FUCHSBICHLER S, HOGENAUER G, TURNOWSKY F: The enoyl- [acyl-carrier-protein] reductase (FabI) of Escherichia coil which catalyzes a key regulatory step in fatty acid biosynthesis, accepts NADH and NADPH as cofactors and is inhibited by palmitoyl-CoA. Eur. Biochem. (1996) 242:689–694.
   PubMedGoogle Scholar
• McMURRY LM, OETHINGER M, LEVY SB: Triclosan targets lipid synthesis. Nature (1998) 394:531–532.
   PubMed Web of Science ®Google Scholar
• HEATH RJ: Bacterial fatty-acid biosynthesis: an antibacterial drug target waiting to be exploited. Drug Discovery Today (2001) 6:715.
   PubMedGoogle Scholar
• LEVY CW, ROUJEINIKOVA A, SEDELNIKOVA S et al.: Molecular basis of triclosan activity. Nature (1999) 398:383–384.
   PubMed Web of Science ®Google Scholar
• PAYNE DJ, DU W, BATESON JH: 13-lactamase epidemiology and the utility of established and novel I3-lactamase inhibitors. Expert Opin. Invest. Drugs(2000) 9:247–261.
   PubMed Web of Science ®Google Scholar
• ••Excellent review on p-lactarnase inhibitors.
   Google Scholar
• MARGOLIS PS, HACKBARTH CJ, YOUNG, DC et al.: Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. (2000) 44:1825–1831.
   PubMed Web of Science ®Google Scholar
• MARGOLIS P, HACKBARTH C, LOPEZ S et al.: Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob. Agents Chemother. (2001) 45:2432–2435.
   PubMed Web of Science ®Google Scholar
• WATKINS WJ, LANDAVERRY Y, LEGER R et al.: The relationship between physicochemical properties, in vitro activity and pharmacokinetic profiles of analogs of the efflux pump inhibitor MC-04,124. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, USA (2001). Abstract 339.
   Google Scholar
• EDMUNDS R, TANIO C, MA P: Splicing a cost squeeze into the genomics revolution. The McKinsey Quarterly (2001) 2:15–18.
   Google Scholar